No­var­tis rides with Bi­cy­cle for new pact on tar­get­ed ra­dio­ther­a­pies

No­var­tis has inked a three-year deal with Bi­cy­cle Ther­a­peu­tics to de­vel­op new tar­get­ed ra­dio­ther­a­pies for can­cer.

No­var­tis will pay Bi­cy­cle $50 mil­lion up­front, with down­stream mile­stones adding up to a po­ten­tial $1.7 bil­lion. In ex­change, Bi­cy­cle will use its virus-based plat­form to dis­cov­er new bi­cyclic pep­tides, which it calls bi­cy­cles, that would be used for ra­dio­ther­a­pies. Those bi­cy­cles would act as a hom­ing bea­con for ra­dioac­tive iso­topes, de­liv­er­ing them to can­cer cells to kill the cells while lim­it­ing ra­di­a­tion to healthy tis­sue.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN